drugset / Trial / NCT05016947

Venetoclax Plus Inotuzumab for B-ALL

NCT05016947

Phase 1 Active not recruiting 23 enrolled Dana-Farber Cancer Institute AbbVie · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is evaluating the safety and efficacy of administering venetoclax and inotuzumab ozogamicin in combination in patients with acute lymphoblastic leukemia (ALL) The names of the study drugs involved in this study are: * Venetoclax * Inotuzumab ozogamicin * Dexamethasone

Timeline

Start
2021-09-24
Primary completion
2023-07-10
Completion
2026-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule Oral
Subject Inotuzumab Ozogamicin Monoclonal antibody Intravenous
Subject Venetoclax Small molecule Oral